H
Haiming Wei
Researcher at University of Science and Technology of China
Publications - 248
Citations - 15065
Haiming Wei is an academic researcher from University of Science and Technology of China. The author has contributed to research in topics: Interleukin 21 & Interleukin 12. The author has an hindex of 58, co-authored 223 publications receiving 11569 citations. Previous affiliations of Haiming Wei include Academy of Medical Sciences, United Kingdom.
Papers
More filters
Journal ArticleDOI
Effective treatment of severe COVID-19 patients with tocilizumab.
Xiaoling Xu,Mingfeng Han,Tiantian Li,Wei Sun,Dongsheng Wang,Binqing Fu,Yonggang Zhou,Xiaohu Zheng,Yun Yang,Xiuyong Li,Xiaohua Zhang,Aijun Pan,Haiming Wei +12 more
TL;DR: Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.
Journal ArticleDOI
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Yonggang Zhou,Binqing Fu,Xiaohu Zheng,Dongsheng Wang,Changcheng Zhao,Yingjie Qi,Rui Sun,Zhigang Tian,Xiaoling Xu,Haiming Wei +9 more
TL;DR: The results demonstrate that excessive non-effective host immune responses by pathogenic T cells and inflammatory monocytes may associate with severe lung pathology and suggest that monoclonal antibodies targeting GM-CSF or interleukin 6 may be effective in blocking inflammatory storms and, therefore, be a promising treatment of severe COVID-19 patients.
Journal ArticleDOI
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Qing Zhang,Jiacheng Bi,Xiaodong Zheng,Yongyan Chen,Hua Wang,Wenyong Wu,Zhengguang Wang,Qiang Wu,Hui Peng,Haiming Wei,Rui Sun,Zhigang Tian +11 more
TL;DR: It is found that TIGIT, but not the other checkpoint molecules CTLA-4 and PD-1, was associated with NK cell exhaustion in tumor-bearing mice and patients with colon cancer.
Journal ArticleDOI
Liver-resident NK cells confer adaptive immunity in skin-contact inflammation.
Hui Peng,Xiaojun Jiang,Yonglin Chen,Dorothy K. Sojka,Haiming Wei,Xiang Gao,Rui Sun,Wayne M. Yokoyama,Zhigang Tian +8 more
TL;DR: The findings of liver-resident NK cells shed new light on the acquisition of memory-like properties of NK cells and their roles in mediating CHS.
Journal ArticleDOI
Why tocilizumab could be an effective treatment for severe COVID-19?
TL;DR: It is suggested that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.